Xcout Intel
Alesta Therapeutics
Alesta Therapeutics is a clinical-stage biotechnology company based in Leiden, Netherlands, dedicated to developing novel oral small-molecule therapies targeting GCN2 for underserved rare diseases.
Subscribe to see Alesta Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alesta Therapeutics at a glance
Alesta Therapeutics is a biotechnology company headquartered in Netherlands. Its most recent funding round, Series A, raised $68M in January 2025. Xcout tracks 8 named people at Alesta Therapeutics, including Ilan Ganot (CEO).
Alesta Therapeutics leadership
- Ilan GanotCEO
- Benit MaruCMO
- Matthias Van WoenselCSO
- Jakub SwierczVP R&D
- John DulosSr. VP Translational&Pharmacology
- Rick DekkerVP, Finance
2 more named people on record for Alesta Therapeutics, with roles, board committees and tenure — see the full roster →
Alesta Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $68M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Alesta Therapeutics news
Investors
Alesta Therapeutics competitors
A few of Alesta Therapeutics's closest competitors — see the full list of competitors and alternatives →
Lisata Therapeutics is a clinical-stage pharmaceutical company headquartered in Basking Ridge, New Jersey, dedicated to developing advanced therapies to improve the treatment of various serious diseases.
Scenic Biotech is a biotechnology company headquartered in Amsterdam, Netherlands, that advances modifier therapy as an approach to treating genetic disorders by uncovering novel genome pathways.
Artica Therapeutics is a Dutch biotechnology company specializing in drug discovery and the development of novel covalent small molecule therapies.
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
AM-Pharma is a biopharmaceutical company based in Utrecht, the Netherlands, focused on developing proprietary recombinant human alkaline phosphatase therapeutics like ilofotase alfa for severe medical conditions.
Leal Therapeutics, Inc. is a biotechnology company headquartered in Worcester, Massachusetts, focused on pioneering first-in-class neuro-metabolic therapeutics to treat patients with severe brain and metabolic health disorders.
Get Alesta Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alesta Therapeutics in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access